| Literature DB >> 33035564 |
Heidrun Männle1, Jutta Hübner2, Karsten Münstedt3.
Abstract
A survey on 5115 beekeepers and 121 patients treated with bee venom by an apitherapy clinic in the Hubei province, the epicenter of COVID-19 in China, reported that none of the beekeepers developed symptoms associated with COVID-19, the new and devastating pandemic. The hypothesis that immunity to bee venom could have a preventive effect was expressed and the authors of the Chinese survey suggested that the next step should be animal experiments on monkeys. We believed that before starting such studies, a second independent survey should verify the findings and define the hypothesis more clearly. Thus we asked all German beekeepers to complete an assessment form which would summarize their experiences with COVID-19. In contrast to the Chinese study we found that two beekeepers had died from a SARS-CoV-2 infection and forty-five were affected. The reaction to bee stings (none; mild swelling; severe swelling) correlated with the perceived severity of the SARS-CoV-2-infection-associated symptoms - exhaustion and sore throat. Beekeepers comorbidity correlated with problems with breathing at rest, fever, and diarrhea. Our results did not confirm the findings of the Chinese study. However, since the antiviral effects of bee venom have been found in several studies, we cannot exclude that there could be a direct preventive or alleviating effect when bee venom is administered during the infection.Entities:
Keywords: Bee venom; Beekeeper; COVID-19; SARS-CoV-2
Mesh:
Substances:
Year: 2020 PMID: 33035564 PMCID: PMC7536547 DOI: 10.1016/j.toxicon.2020.10.004
Source DB: PubMed Journal: Toxicon ISSN: 0041-0101 Impact factor: 3.033
Characteristics of beekeepers in the various groups.
| Entire group | Beekeepers infected by SARS-CoV-2 | Beekeepers in contact with SARS-CoV-2 infected people | Beekeepers in contact with possibly SARS-CoV-2 infected people | |
|---|---|---|---|---|
| Age [years] (mean; (SD)) | 54.6 (13.3) | 52.0 (14.4) | 55.0 (12.6) | 55.4 (13.4) |
| Gender [N (%)] | ||||
| Female | 54 (23.1) | 7 (15.6) | 31 (31.3) | 16 (17.8) |
| Male | 179 (76.5) | 38 (84.4) | 68 (68.7) | 73 (81.1) |
| missing | 1 (.4) | – | – | 1 (1.1) |
| Beekeepers with comorbidity [N (%)] | 66 (28.2) | 14 (31.1) | 30 (30.3) | 22 (22.4) |
| Time being a beekeeper [years] (mean; (SD)) | 14.1 (14.3) | 12.0 (10.1) | 12.6 (12.9) | 16.6 (17.1) |
| Estimated total number of bee stings [N] (mean; (SD)) | 567 (1619) | 297 (495) | 450 (1300) | 835 (2188) |
| Number of bee stings in 2020 [N] (mean; (SD)) | 28 (114) | 14 (24) | 20 (30) | 44 (182) |
| Reaction to bee stings [N (%)] | ||||
| None | 35 (15.0) | 4 (8.9) | 14 (14.1) | 17 (18.9) |
| mild swelling | 138 (59.0) | 33 (73.3) | 57 (57.6) | 48 (53.3) |
| severe swelling | 58 (24.8) | 8 (17,8) | 28 (28.3) | 22 (24.4) |
| missing | 3 (1.3) | – | – | 3 (3.3) |
| Signs of allergy on bee sting [N (%)] | ||||
| none | 156 (66.7) | 29 (64.4) | 59 (59.6) | 68 (75.6) |
| itching | 66 (28.2) | 15 (33.3) | 31 (31.3) | 20 (22.2) |
| rash | 11 (4.7) | 1 (2.2) | 8 (8.1) | 2 (2.2) |
| Shortness of breath/drop in blood pressure | 1 (.4) | – | 1 (1.0) | – |
Comorbidities in the various groups.
| Entire group | Beekeepers infected by SARS-CoV-2 | Beekeepers in contact with SARS-CoV-2 infected people | Beekeepers in contact with possibly SARS-CoV-2 infected people | |
|---|---|---|---|---|
| Beekeepers with comorbidity [N (%)] | 66 (28.2) | 14 (31.1) | 30 (30.3) | 22 (22.4) |
| Hypertension | 9 (3.8) | 1 (2.2) | 3 (3.0) | 5 (5.6) |
| Asthma | 7 (3.0) | 1 (2.2) | 4 (4.0) | 2 (2.2) |
| Bronchitis, COPD | 5 (2.1) | – | 2 (2.0) | 3 (3.3) |
| Diabetes | 4 (1.7) | 1 (2.2) | 2 (2.0) | 1 (1.1) |
| Hay fever | 4 (1.7) | 1 (2.2) | 1 (1.0) | 2 (2.2) |
| Rheumatism/arthrosis | 5 (2.1) | 2 (4.4) | 2 (2.0) | 1 (1.1) |
| Bee venom allergy | 3 (1.3) | 1 (2.2) | 2 (2.0) | – |
| Hypertension and diabetes | 3 (1.3) | – | 2 (2.0) | 1 (1.1) |
| Hypothyroidism | 3 (1.3) | 1 (2.2) | 2 (2.0) | – |
| Cardiac insufficiency | 2 (.9) | – | 1 (1.0) | 1 (1.1) |
| Coronary heart disease | 2 (.9) | 1 (2.6) | 1 (1.0) | – |
| Asthma, bee venom allergy | 1 (.4) | – | 1 (1.0) | – |
| Asthma, ulcerative colitis and bee venom allergy | 1 (.4) | 1 (2.2) | – | – |
| Atopic dermatitis | 1 (.4) | – | 1 (1.0) | – |
| Atrial fibrillation | 1 (.1) | – | – | 1 (1.1) |
| Breast cancer | 1 (.4) | – | – | 1 (1.1) |
| Herpes zoster | 1 (.4) | – | – | 1 (1.1) |
| Hypertension and migraine | 1 (.4) | – | – | 1 (1.1) |
| Hypertension and bee venom allergy | 1 (.4) | – | – | 1 (1.1) |
| Hay fever and asthma | 1 (.4) | – | 1 (1.0) | – |
| Hypercholesterolemia and reflux esophagitis | 1 (.4) | – | 1 (1.0) | – |
| Heart valve replacement | 1 (.4) | – | 1 (1.0) | – |
| Kidney dysfunction | 1 (.4) | 1 (2.2) | – | – |
| Migraine | 1 (.4) | 1 (2.2) | – | – |
| Multiple sclerosis | 1 (.4) | – | 1 (1.0) | – |
| Multiple sclerosis and epilepsy | 1 (.4) | – | 1 (1.0) | – |
| Sarcoidosis | 1 (.4) | 1 (2.2) | – | – |
| Ulcerative colitis | 1 (.4) | 1 (2.2) | – | – |
| Missing | 2 (.9) | – | 1 (1.0) | 1 (1.1) |
Fig. 1Severity of symptoms in beekeepers affected with SARS-CoV-2 as assessed by the Triage-Fragebogen grippaler Infekt/Influenza/Corona” by Dielmann-von Berg, Scherer and Mühlenfeld (n = 45).
Additional measures taken against COVID-19.
| Beekeepers in contact with SARS-CoV-2 infected people | Beekeepers in contact with possibly SARS-CoV-2 infected people | |
|---|---|---|
| Number of beekeepers who used preventive measures [N (%)] | 29 (29.3) | 25 (27.8) |
| Propolis [N] | 9 | 9 |
| Diet [N] | 5 | 2 |
| Propolis in combination with honey and/or royal jelly and/or pollen [N] | 1 | 4 |
| Exercise [N] | 0 | 5 |
| Diet and exercise [N] | 3 | – |
| Diet and vitamin C [N] | 2 | – |
| Honey [N] | 2 | 0 |
| Vitamin C and exercise [N] | 0 | 2 |
| Propolis and vitamin C [N] | – | 1 |
| Propolis and diet [N] | 1 | 0 |
| Propolis and zinc [N] | 1 | 0 |
| Vitamin C [N] | 1 | 0 |
| Vitamin C, Vitamin D, selenium [N] | 1 | 1 |
| Vitamin D [N] | 1 | 1 |
| Homoeopathy [N] | 1 | 0 |
| Sauna [N] | 1 | 0 |